Invivyd Shares New Data on Pemivibart's Neutralization of COVID Variants, Details Virus Evolution
Portfolio Pulse from Benzinga Newsdesk
Invivyd, Inc. (NASDAQ:IVVD) shared new data on the neutralization activity of its drug pemivibart against various COVID-19 variants. The data shows stable neutralization results across a range of variants, with no significant mutational changes in the drug's binding site since the Omicron variant. Invivyd collaborates with LabCorp's Monogram Biosciences for virology assessments, ensuring the drug's efficacy against evolving SARS-CoV-2 variants.
September 23, 2024 | 11:03 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Invivyd's new data on pemivibart shows stable neutralization against COVID-19 variants, with no significant changes in the drug's binding site. This supports the drug's continued efficacy.
The data indicates that pemivibart remains effective against current COVID-19 variants, which is positive for Invivyd's product portfolio and market position. The collaboration with LabCorp adds credibility to the findings, potentially boosting investor confidence.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100